Moderna CEO Stéphane Bancel deflected concerns about the new presidential administration's potential impact on life sciences ...
Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...
A member of the U.K. Parliament is calling for regulators to audit pharmaceutical companies that have made misleading ...
Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...
An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...
Moderna Inc.’s stock erased early losses to gain 3.4% on Friday, after the biotech company posted a wider-than-expected ...
Moderna Inc. (NASDAQ:MRNA) reported a fourth-quarter EPS loss of $(2.91), missing the consensus of $(2.62), a turnaround from ...
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Moderna reported a Q4 EPS loss of $2.91, missing estimates, with revenue down 66% YoY to $966 million. The company reaffirmed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback